Patents Examined by Daniel E. Kolker
  • Patent number: 10975157
    Abstract: The invention provides antibodies immunoreactive with human OX40 and methods of using the same. The antibodies are reactive with a portion of the C-terminus of the human OX40 protein that includes amino acids 266-277. The antibodies are useful for detecting OX40 protein expression in human tissue samples, including by immunohistochemistry, immunofluorescence, or immunoblot.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 13, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Yifei Zhu, Zhiming Liao, Robert Pytela
  • Patent number: 10974166
    Abstract: One embodiment of the present invention is a protein having affinity for an immunoglobulin, which is a protein having two or more domains derived from any of the amino acid sequences of E, D, and A domains of protein A, and in the amino acid sequence of at least one of the domains, one or more lysines are included, and the C-terminal lysine is deleted or substituted, or a protein having affinity for an immunoglobulin, which is a protein having two or more domains derived from any of B, C, and Z domains of protein A, and in the amino acid sequence of at least one of the domains, one or more lysines are included, and lysine at position 4 and the C-terminal lysine are deleted or substituted.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 13, 2021
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Shoya Yoda, Satoru Misawa, Risa Nakata
  • Patent number: 10947305
    Abstract: The present invention is directed to novel Anti-TNF? antibody binding compounds and methods of using the same. Anti-TNF? antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNF? antibody binding compound. The invention further provides the use of an Anti-TNF? antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: March 16, 2021
    Assignee: Full Spectrum Genetics, Inc.
    Inventors: Robert DuBridge, Veronica Juan
  • Patent number: 10940401
    Abstract: The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 9, 2021
    Assignee: GENENTECH, INC.
    Inventors: Ekta Mahajan, Joanna So, Jay Werber
  • Patent number: 10941178
    Abstract: The present disclosure relates generally to methods of producing, processing, or purifying antibodies. The present disclosure also relates to methods of producing, processing, or purifying a target antibody from cell cultures to remove host cell proteins.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: March 9, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Nooshafarin Sanaie, Brian Kluck, Andrew Quezada, Robert vonder Reith, Chi Tran, James Woo
  • Patent number: 10927164
    Abstract: The present invention provides a method for recovering a human VH3 domain-containing antibody in monomeric form. In particular the present invention provides a new method that allows recovery of monomeric human VH3 domain-containing antibodies from a mixture containing monomeric and multimeric forms of the antibody.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 23, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild
  • Patent number: 10920193
    Abstract: Described herein are chemically defined, adherent culture protocols for generating functional motor neurons characteristic of diverse hindbrain and spinal cord regions, with high efficiency.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: February 16, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ethan Scott Lippmann, Neha Sehgal, Randolph Scott Ashton
  • Patent number: 10919930
    Abstract: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: February 16, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Peter S. Gagnon
  • Patent number: 10912955
    Abstract: A process is provided for inhibiting symptoms of celiac disease, Clostridium difficile associated diseases such as Clostridium difficile colitis, pseudomembranous colitis and antibiotic associated diarrhea, food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgM. When administered in a, therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: February 9, 2021
    Inventor: Michael R. Simon
  • Patent number: 10914748
    Abstract: The present description relates to methods for clinically assessing Parkinson's disease in a subject using erythrocyte-derived extracellular vesicles (EEV) as a biomarker.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: February 9, 2021
    Assignee: Université Laval
    Inventors: Francesca Cicchetti, Eric Boilard, Steve Lacroix, Isabelle St-Amour
  • Patent number: 10906934
    Abstract: The invention provides methods of reducing fouling of ultrafiltration membranes in processes wherein virus particles are removed from aqueous solutions comprising virus particles and at least one protein by adding a surfactant or non-surfactant, non-ionic agent to the aqueous solution prior to filtration. The invention also provides methods to dissociate protein aggregates or to reduce the formation of protein aggregates by adding a surfactant or non-surfactant, non-ionic agent to the protein solution.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: February 2, 2021
    Assignee: GENENTECH, INC.
    Inventors: Arick Brown, Junyan Ji, Jun Liu, Yuchang John Wang
  • Patent number: 10906981
    Abstract: Provided herein are compositions, kits, methods and systems related to administering a structure that crosses the blood brain barrier (BBB) along with a monosaccharide, either simultaneously or consecutively. The structure may be, for example an antibody or fusion antibody that binds to an insulin receptor.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: February 2, 2021
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10906935
    Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: February 2, 2021
    Assignees: United Therapeutics Corporation, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: David Meh, Timothy Atolagbe, G. Mark Farquharson, Samir Shaban, Mary Koleck, George Mitra
  • Patent number: 10899839
    Abstract: Methods for inhibiting degeneration of a neuron, methods of treating a neurological/neurodegenerative disease, methods of modulating the directional growth of a neuron, and methods of interfering with the interaction of Wnt and Ryk are provided herein. Also provided are isolated anti-Ryk antibodies and antibody fragments that specifically bind to a binding domain of Wnt.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: January 26, 2021
    Assignee: Tire Regents of the University of California
    Inventor: Yimin Zou
  • Patent number: 10894806
    Abstract: The invention relates to a process for the selective concentration of immunoglobulins or other proteins that contain an Fc domain (target protein), comprising the following steps: a. preparing a solution that contains the target protein; b. incorporating an Fc-binding protein with precisely two binding sites under conditions that allow binding to occur; c. separating the precipitate from the liquid phase; d. undoing the binding of the target protein from the Fc-binding protein.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: January 19, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dorothee Ambrosius, Michael Dieterle, Philine Dobberthien, Maria-Katharina Wiegeshoff
  • Patent number: 10888841
    Abstract: Provided is an affinity chromatography carrier having an excellent purification purity, including a substrate, a hydrophilic polymer, and an affinity ligand, in which the substrate is constituted of at least one selected from the group consisting of a polysaccharide, an acrylate-based polymer, a methacrylate-based polymer and a styrene-based polymer, the hydrophilic polymer is at least one selected from the group consisting of hydrophilic polysaccharides, the affinity ligand is at least one selected from the group consisting of an antibody-binding protein and an antibody-binding polypeptide, a carboxy group is introduced into the affinity chromatography carrier, and the amount of the carboxy group introduced is 15 mmol/L-gel to 60 mmol/L-gel in terms of ion exchange capacity.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: January 12, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Shiori Kihara
  • Patent number: 10881694
    Abstract: This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling. The formation of this signaling module is dependent on cholesterol for its formation and provides a mechanistic explanation for the protective effects of cholesterol depleting drugs in several non-neural models of cell death. As such, the formation of the signaling module lends itself as a novel screen for the identification of new drugs and therapeutics which would retard its formation and protect against neuronal injury and death.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 5, 2021
    Inventor: Adil A. Khan
  • Patent number: 10865372
    Abstract: An object is to provide a neuron cultivation device which promptly develops bundles of axons extending from neurons in vitro. A device for cultivating neuron with axon, the device comprising a cultivation plate and a plurality of modules arranged in the cultivation plate. Each of the modules includes at least one of first chambers receivable of cell bodies of neurons at least one of second chambers, and at least one of channels receivable of a bundle of axon extended from the cell bodies. The channels connect the first chambers and the second chambers. Bottom ends of the first chambers, the second chambers and the channels are closed and top ends of the first chambers and the second chambers are open.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: December 15, 2020
    Assignee: THE FOUNDATION FOR THE PROMOTION OF INDUSTRIAL SCIENCE
    Inventors: Teruo Fujii, Yoshiho Ikeuchi, Shohei Kaneda, Jiro Kawada
  • Patent number: 10865224
    Abstract: The present invention relates to improved processes and systems for purification of biological molecules, where the processes can be performed in a continuous manner.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 15, 2020
    Assignee: EMD Millipore Corporation
    Inventors: Alex Xenopoulos, Michael Phillips, Wilson Moya, Jad Jaber, Mikhail Kozlov, Ajish Potty, Matthew T. Stone, William Cataldo, Christopher Gillespie
  • Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi